Impact of reduced tobacco smoking on lung cancer mortality in the united states during 1975-2000 by Moolgavkar, S. (Suresh) et al.
jnci.oxfordjournals.org   JNCI | Articles 541
DOI: 10.1093/jnci/djs136 © The Author(s) 2012. Published by Oxford University Press.
Advance Access publication on March 14, 2012. This is an Open Access article distributed under the terms of the Creative Commons Attribution
 Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted
 non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
After the US Surgeon General’s first report on Smoking and 
Health was issued in 1964, several initiatives, collectively known 
as “tobacco control,” included restrictions on smoking in public 
places, large increases in cigarette excise taxes, reduced access to 
cigarettes, and increased public awareness of the hazards of smoking. 
These smoking regulations have been cited as the principal con-
tributors to the observed decline in US adult tobacco use from 
1975 to 2003 (1,2) and to subsequent declines in smoking-related 
mortality (3). In 2004, the Surgeon General (4) estimated that 
during 1965–1999, approximately 3 million lung cancer deaths 
(2.2 million among men and 0.8 million among women) in the 
United States were attributable to smoking. Using a straightforward 
demographic projection, Thun and Jemal (5) estimated that reduc-
tions in tobacco smoking averted approximately 146 000 lung cancer 
deaths among US men during 1991–2003.
In this article, we analyzed the direct influence that changes in 
smoking behaviors that began in the mid-1950s had on lung cancer 
mortality rates among men and women aged 30-84 years in the 
United States during 1975–2000. We also estimated the total 
number of lung cancer deaths averted among men and women 
during the same period as a direct result of changes in smoking 
behavior. Finally, we estimated the numbers of avoidable deaths, 
that is, the number of lung cancer deaths that could have been 
averted had smoking been completely eliminated as of 1965.
Methods
A consortium of six universities and research centers (Erasmus 
Medical Center [Erasmus MC], Rotterdam, the Netherlands; Fred 
Hutchinson Cancer Research Center [FHCRC], Seattle, WA; 
Pacific Institute for Research and Evaluation [PIRE], Calverton, 
MD; Rice University and M.D. Anderson Cancer Center [Rice-
MDA], Houston, TX; Massachusetts General Hospital and Harvard 
Medical School [MGH-HMS], Cambridge, MA; and Yale University, 
New Haven, CT) developed independent models to estimate the 
impact of tobacco control policies on lung cancer mortality. 
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Although the models shared common inputs, each group developed 
its own model, based on mathematical descriptions of lung carci-
nogenesis as it relates to smoking behaviors. The models explicitly 
consider factors associated with the risk of smoking, including the 
number of cigarettes smoked per day, the age of initiation, and the 
number of years quit.
All models shared the same overall structure (Figure 1). The 
central component of each model was a dose–response module that 
provided a quantitative description of the age-specific lung cancer 
mortality among never smokers and age-specific lung cancer 
mortality among continuing smokers and former smokers by detailed 
history of smoking. This module was used to predict age-specific 
lung cancer mortality rates associated with three specific smoking 
scenarios. With the exception of the MGH-HMS group, which 
used a set of logistic regression models and tumor progression 
functions (6,7), the other groups used multistage models (8–11) for 
the underlying dose–response module. Multistage models, based 
on mathematical formalisms representing the biological paradigm of 
initiation, promotion, and progression, recognize that carcinogenesis 
includes accumulation of mutations and clonal expansion of partially 
altered cells on the pathway to malignancy (8,12–17). These models 
may be used to explore biological hypotheses regarding the mech-
anism of tobacco-induced lung cancer. They have generally shown 
clonal expansion (promotion) of partially altered (initiated) cells 
by cigarette smoke to be the dominant mechanism and have 
confirmed the disproportionate importance of smoking duration on 
lung cancer risk (10,11,18–21). Both the multistage models and the 
probabilistic model of MGH-HMS are capable of accommodating 
detailed individual-level smoking histories, including temporal 
factors, such as age at start, age at cessation, and temporal changes 
in the level of smoking. The parameters of these models were 
estimated as described in the supplementary material (available 
online) by fitting the model to specific epidemiological cohort data 
(Erasmus MC, FHCRC, PIRE, Yale), case–control data (Rice-MDA), 
or registry data (MGH-HMS). The Erasmus, FHCRC, and Yale 
model parameter estimates were obtained by fits of the Two-Stage 
Clonal Expansion (TSCE) model to the Nurses Health Study 
(NHS) and Health Professionals Follow-up Study (HPFS) cohort 
data (11). The model parameters for the PIRE model were derived 
by fitting the TSCE model to the Cancer Prevention Study II 
(CPS II) data (10). The parameters for the Rice-MDA model were 
derived from fitting the TSCE model to data from a case–control 
study conducted to evaluate the interaction of smoking and genetics 
on lung cancer risk (21). The parameters for the MGH-HMS model 
were estimated by fitting a nested set of logistic regression models 
for cancer development and spread along with a tumor growth 
function to lung cancer incidence in the Surveillance, Epidemiology, 
and End Results (SEER) registry during the period 1990–2000 (6,7).
Three specific smoking scenarios, the common inputs for the 
models, were simulated using a smoking history generator as briefly 
described below. Each involved a detailed description of smoking 
behaviors by sex and birth cohort starting with the birth cohort of 
1890 and ending with the birth cohort of 1970. The actual tobacco 
control (ATC) scenario is a quantitative description of the actual 
smoking behaviors of men and women in the United States. The 
no tobacco control (NTC) scenario is a quantitative description of 
the predicted smoking behaviors of men and women in the United 
States under the assumption that tobacco control efforts starting 
mid-century had never been implemented. Initiation rates in the 
NTC scenario are from models fitted to survey data after age and 
cohort effects had stabilized. For men, these are cohorts born after 
1904. The history for women is more complex because age effects 
stabilized after 1919 but cohort effects continued to increase; 
therefore, a linear cohort trend for 1930–1955 was used in the 
model for log rate, and the estimated parameter was held constant 
after 1955. For smoking cessation rates, we used data for individuals 
born in 1900–1904 because they would have had little knowledge 
of the health effects of smoking for most of their lives while at the 
same time being sufficiently well represented in surveys to provide 
accurate estimates of these rates. The complete tobacco control 
(CTC) scenario is a quantitative description of the predicted 
smoking behaviors of men and women in the United States under 
the assumption that all smoking ceased abruptly in 1965, that is, all 
CONTEXT AND CAVEATS
Prior knowledge
The proportion of smokers among the US population has gradually 
declined since the mid-1950s, as the dangers of tobacco use became 
apparent and tobacco control laws were enacted. However, there 
are few estimates of how many lung cancer deaths were spared by 
the decline in cigarette smoking.
Study design
Six groups of investigators built independent models based on 
cohort, case–control, or registry data and calibrated to mortality or 
other data to estimate the number of lung cancer deaths averted in 
1975–2000. The data were stratified by sex and birth decade (1890–
1970), and the prevalence of smoking and lung cancer deaths under 
three scenarios were considered: actual tobacco control (ATC), 
based on historical changes in smoking rates; no tobacco control 
(NTC), based on predicted smoking rates if tobacco control had not 
been enacted; and complete tobacco control (CTC), which considers 
what might have happened if all smoking ceased in 1965.
Contribution
In the United States in 1975–2000, there were 2 067 775 lung cancer 
deaths among men and 1 051 978 lung cancer deaths among women. 
The models predict that over 550 000 lung cancer deaths among men 
and over 240 000 lung cancer deaths among women were averted 
by tobacco control efforts. If all smokers had quit in response to the 
Surgeon General’s first report in 1964, over 1.6 million lung cancer 
deaths might have been averted among men, and over 880 000 
among women.
Implication
Tobacco control efforts do appear to have reduced smoking behav-
ior and lung cancer deaths.
Limitations
There is some variation in the estimates among models, depending 
on data source and calibration. Data were not available for other 
exposures related to lung cancer incidence and non-cigarette forms 
of tobacco use were not considered. The relative contributions of 
decreased smoking initiation and increased smoking cessation 
were not addressed.
From the Editors
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during the period 1975–2000 for individuals born between 1890 
and 1970. As an example, we show one output of the smoking 
history generator, the proportion of current smokers in the three 
smoking scenarios (Figure 2). For the ATC scenario, the initial 
increase in smoking prevalence for each cohort results primarily 
from initiation and the subsequent decline reflects both smoking 
cessation and increased mortality among smokers. Deaths from 
causes other than lung cancer were also simulated by the level of 
smoking; each individual history was terminated at 84 years or at 
the age of death from a cause other than lung cancer if the death 
occurred before 84 years. Details of the construction of the 
smoking history generator can be found on the CISNET website 
(http://cisnet.cancer.gov and supplementary material, available 
online). Using the outputs of the smoking history generator, each 
group estimated the number of lung cancer deaths during the pe-
riod 1975–2000 while adjusting for other-cause mortality in each 
smoking scenario.
Results
The models yielded a range of results for the numbers of lung 
cancer deaths among the three smoking scenarios, but the esti-
mates of the fraction of lung cancer deaths averted were reasonably 
consistent across models. For purposes of illustration, we chose 
one of the models calibrated against the US population data (the 
Yale model) as an exemplar model to present our results (Figure 3). 
Based on this model, we could estimate the actual age-adjusted 
rates and the actual number of lung cancer deaths among men and 
women aged 30-84 years in the United States during the period 
1975–2000 and the numbers that would have been expected assuming 
the NTC and CTC scenarios. During the period 1975–2000, there 
were 2 067 775 lung cancer deaths among men and 1 051 978 lung 
cancer deaths among women in the United States. Assuming NTC 
conditions, the Yale model estimated 2 670 897 lung cancer deaths 
among men and 1 273 151 lung cancer deaths among women, 
whereas assuming CTC conditions, the deaths numbered 958 862 
and 438 858, respectively, among men and women. The difference 
between the NTC and observed numbers provides an estimate of 
the numbers of lung cancer deaths averted (A), which for the Yale 
model are 603 122 and 221 173 for men and women, respectively. The 
difference between NTC and CTC (B) is an estimate of the total 
number of lung cancer deaths that could have been averted if tobacco 
control efforts had been immediately and completely successful with 
all smoking ending in 1965, which were approximately 1 712 035 and 
834 293 for men and women, respectively, in the Yale model. The 
averages for these figures across all models are 1 620 686 and 883 356.
We also examined the difference between the NTC and observed 
numbers to obtain an estimate of the numbers of lung cancer 
deaths averted in all models. Approximately 795 851 US lung cancer 
deaths were averted. The high estimate for men was 658 529, the 
low estimate was 454 517, and the average was 552 574 (Table 1). 
For women, the high estimate was 333 976, the low estimate was 
201 788, and the average was 243 277. When we looked at the 
difference between NTC and CTC, again, as an estimate of the 
total number of lung cancer deaths that could have been averted 
if tobacco control efforts had been immediately and completely 
successful, we estimated that approximately 2 504 042 lung cancer 
smokers quit permanently at that time and there was no initiation 
of smoking after 1964. Clearly, the CTC scenario represents the 
best imaginable outcome for smoking behavior. Our justification 
for using this scenario is that it is transparent and unambiguous. 
More details about the construction of these scenarios are on the 
Cancer Intervention and Surveillance Modeling Network (CISNET) 
web site (http://cisnet.cancer.gov last accessed Feb 19, 2012) and 
in a forthcoming group of articles (22).
The models used in CISNET did not incorporate other known 
or suspected risk factors, such as environmental tobacco smoke, 
radon exposure, diet, and air pollution (23–25), which could have 
influenced trends in lung cancer mortality in the United States. 
Moreover, the datasets from which the parameters of the individual 
dose–response modules were estimated may not be representative 
of the US population. For these reasons, the outputs of the models 
under the ATC scenario cannot be expected to reproduce the 
observed lung cancer rates in the US population. Rather, without 
further calibration, these models estimate lung cancer rates in 
hypothetical populations with the same smoking behaviors and the 
same age structure as the US population in 1975–2000. To com-
pensate for these limitations, some groups (FHCRC, MGH-HMS, 
Yale, PIRE) chose to calibrate their models further to describe 
actual deaths in the US population under the ATC scenario during 
the period 1975–2000. In the models of the FHCRC, MGH-HMS, 
and Yale groups, this calibration was achieved by embedding 
the dose–response module in an age–period–cohort model. The 
exception was the PIRE model, which used only a period calibration. 
Other groups (Erasmus MC, Rice-MDA) chose not to perform 
this additional calibration. The overall model structure and the 
specific models used by each group are described in greater detail 
in the supplementary materials (available online).
For each smoking scenario (ATC, NTC, CTC), the smoking 
history generator provided, as its output, detailed smoking histories 
Figure 1. Process shared by all models. Population and smoking inputs 
were used to develop the smoking history generator, which, in turn, 
simulates detailed individual-level smoking and other-cause mortality 
histories. These individual histories were used by each of the modeling 
groups to estimate lung cancer mortality rates in the population.
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deaths could have been averted in men and women combined. 
This estimate represents the average of the estimates for the 
models shown in Table 1. In the year 2000 alone, approximately 
70 218 lung cancer deaths were averted: 44 135 among men and 
26 083 among women. These numbers are estimated to represent 
approximately 32% of lung cancer deaths that could have potentially 
been averted during the period 1975–2000, 38% of the lung cancer 
deaths that could have been averted in 1991–2000, and 44% of 
lung cancer deaths that could have been averted in 2000.
The other models calibrated to US mortality yielded similar 
estimates of the number of lung cancer deaths among the three 
scenarios (data not shown). Counts of the differences in the 
number of deaths between scenarios are shown for all models in 
Table 1 and in Supplementary Figure 1 (available online). The 
ratio of deaths averted to total deaths that could potentially have 
been avoided (ie, A/B) is also presented in Table 1. The models 
estimate that of all avoidable deaths from smoking-related lung 
cancer, between 24% and 32% among women and between 30% 
and 37% among men were actually averted as a result of the 
changes in smoking behaviors that actually began in the mid-1950s 
some years before the first Surgeon General’s Report. For both 
sexes combined, approximately 32% (28%–35% across models) of 
all avoidable deaths were averted. Table 1 also shows the impact 
of tobacco control efforts on lung cancer mortality for the decade 
1991–2000 and for the year 2000. In the decade 1991–2000, the 
fraction of lung cancer deaths averted in men and women combined 
increased to about 38% (34%–43% across models). In the year 2000, 
this fraction increased to roughly 44% (39%–50% across models). 
The increasing trend in the fraction of lung cancer deaths averted 
reflects both changes in smoking behaviors and a continuing decrease 
in risk among former smokers.
Discussion
A consortium of six research groups used data from common 
sources to recreate detailed cigarette smoking histories under three 
Figure 2. Percentage of current smokers in the US population by sex and birth cohort, assuming three different tobacco control scenarios. This is 
one of the outputs that can be generated from the smoking history generator. The output from the actual tobacco control scenario describes the 
observed data well (not shown).
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distinct tobacco control scenarios as inputs for mathematical models 
to quantify the impact of changing smoking behavior on lung cancer 
mortality rates in the United States during 1975–2000. We used a 
comparative modeling approach to address this complex problem; 
comparative modeling produces a range of results across models 
but, when these are reasonably consistent, enhances their credibility. 
During the period 1975–2000, approximately 2 504 042 lung cancer 
deaths among men and women combined could have been averted 
had tobacco control efforts been completely effective in eliminating 
smoking as of 1965; of these, we estimate that approximately 795 851 
lung cancer deaths were averted or about one-third of what was 
possible. During the period 1991–2000, we estimate that approxi-
mately 345 000 lung cancer deaths among US men and 175 000 
deaths among US women were averted due to changes in smoking 
behaviors starting in the mid-1950s. These estimates of reduced 
lung cancer mortality associated with reduced tobacco use are much 
larger than an estimate from demographic projections that 146 000 
lung cancer deaths among men were averted in 1991–2003 (5). We 
estimate that in the year 2000 alone, approximately 44 000 deaths 
were averted among US men and 26 000 deaths among US women.
It is not surprising that the various models used in this article 
yielded a range of estimates of the fraction of lung cancer deaths 
averted by the tobacco control efforts in the United States. This 
range of results represents the uncertainty associated with model 
choice. First, some of these models were calibrated against US 
mortality data, and, as a consequence, these models describe the 
lung cancer mortality trends in the United States very well under 
the ATC scenario. Second, although five of the six groups used the 
TSCE version of multistage models (8,10,11) as the dose–response 
module, the estimated parameters were different because they were 
estimated by their fit to different cohorts. In addition to the TSCE 
model, the Yale group also used the models developed by Knoke 
et al. (9) and Flanders et al. (26) and obtained similar estimates of 
the relative effect of tobacco control. It is well known that the risks 
of tobacco smoking have changed over time; moreover, they could 
be modified by other factors such as diet that are not accounted for 
in any of the models. Despite these limitations, the estimated 
numbers of deaths averted and deaths that could have been averted 
under the assumption of CTC were reasonably consistent across 
models (Table 1). The main message of these analyses is clear. 
Tobacco control strategies implemented mid-century have averted 
hundreds of thousands of lung cancer deaths in the United States 
during the period 1975–2000, but these are only approximately 
30% of the lung cancer deaths that could have been averted had all 
cigarette smoking ended in 1965.
The FHCRC, MGH-HMS, and Yale groups calibrated their 
models to US mortality during 1975–2000 using birth cohort and 
period effects. These calibrations are necessary to describe lung 
cancer mortality rates and trends in the United States and indicate 
that the lung cancer mortality experience of the entire population 
cannot be adequately described by extrapolating from the SEER 
registry in one decade, or from various cohort and case–control 
Figure 3. Lung cancer death rates and counts for men and women aged 30-84 years as observed and for modeled tobacco control scenarios. 
ATC = Actual Tobacco Control; CTC = Complete Tobacco Control; NTC = No Tobacco Control.
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studies of smoking and lung cancer (please see the supplementary 
material, available online, for the datasets used by each of the 
groups for parameter estimation). Particularly among men, US lung 
cancer mortality is considerably higher than would be expected from 
the cohort studies against which the dose–response modules were 
calibrated. In addition, models from cohort studies and available popu-
lation smoking histories cannot adequately describe temporal compo-
nents of trend, that is, the effects of age, period, and birth cohort.
There could be several reasons why the models were poor 
at predicting population lung cancer rates without additional 
calibrations. First, the datasets used for estimating the parameters 
of the dose–response modules were almost certainly not represen-
tative of the US population. Second, the smoking history generator 
was based on smoking histories for birth cohorts in the general 
population that were inferred from simulations using cross-sectional 
histories that often relied on subjects’ recall of events that occurred 
several years earlier. Third, potentially important covariates (eg, diet, 
air pollution, and radon exposure) and occupational exposures 
(including asbestos and ionizing radiation) were not available for the 
overall population, and different exposure distributions could con-
tribute to rate discrepancies. Fourth, although the models discussed 
assume a consistent effect of exposure on lung cancer mortality, 
temporal changes in the manufacture of cigarettes and smoking 
behaviors could explain some of the discrepancies in trend, and data 
on changes in cigarette manufacturing and composition are not 
readily available. Changes in tobacco or cigarette composition, which 
were not explicitly addressed in these analyses, could be important 
contributors to population trends in lung cancer mortality. However, 
one would expect changes in tobacco or cigarette composition to 
manifest themselves as period effects, whereas models that used 
age–period–cohort calibrations find that trends are dominated by 
birth cohort effects. Finally, uncertainty remains with respect to 
the models themselves.
In particular, our estimates of the lung cancer rates in the 
US population under the CTC scenario appear to be higher than 
would have been expected on the basis of recent work on lung 
cancer rates among never smokers (27). However, for the reasons 
given above (cohorts not representative of the general population, 
omission of important covariates), the never-smoker rates reported 
by Thun et al. (27) may not reflect the never-smoker rates in the 
general population. Some confidence in the lung cancer rates under 
the CTC scenario estimated from the models in this article can be 
derived from the fact that the dose–response modules describe 
lung cancer rates among former smokers well (9,10,11).
One limitation of the calibrations is that the same period and 
cohort parameters are applied to current smokers, former smokers, 
and never smokers. Factors, such as diet, that could affect trends 
in lung cancer rates might be expected to have different effects 
among current smokers, former smokers, and never smokers. 
However, different cohort and period effects could not be estimated 
Table 1. Realized and potential reductions in lung cancer mortality from changes in smoking behavior among men and women aged 
30-84 years.*
Realized proportion  
of potential benefit  
from tobacco  
control, by year(s)
Women Men Overall
Realized  
(NTC–ATC)
Potential  
(NTC–CTC)
Proportion  
realized
Realized  
(NTC–ATC)
Potential  
(NTC–CTC)
Proportion  
realized
Realized  
(NTC–ATC)
Potential  
(NTC–CTC)
Proportion 
realized
1975–2000         
 Erasmus MC 201 788 806 ,320 0.25 658 529 1 757 857 0.37 860  317 2  564  177 0.34
 FHCRC 202 817 862 ,610 0.24 508 777 1 680 867 0.30 711  594 2  543  477 0.28
 MGH-HMS 214 830 854 112 0.25 487 263 1 597 733 0.30 702  092 2  451  845 0.29
 PIRE 333 976 1 064 443 0.31 454 517 1 329 972 0.34 788  493 2  394  415 0.33
 Rice-MDA 285 079 878 359 0.32 603 236 1 645 651 0.37 888  316 2  524  010 0.35
 Yale 221 173 834 293 0.27 603 122 1 712 035 0.35 824  294 2  546 328 0.32
 Mean 243 277 883 356 0.28 552 574 1 620 686 0.34 795  851 2 504 042 0.32
1991–2000         
 Erasmus MC 143 273 462 528 0.31 384 882 834 310 0.46 528  155 1 296 837 0.41
 FHCRC 152 574 521 040 0.29 318 279 842 602 0.38 470  853 1 363 642 0.35
 MGH-HMS 153 549 511 509 0.30 310 210 846 300 0.37 463  759 1 357 809 0.34
 PIRE 253 711 687 156 0.37 342 558 865 306 0.40 596  269 1 552 462 0.38
 Rice-MDA 185 782 461 559 0.40 346 266 785 168 0.44 532  048 1 246 727 0.43
 Yale 157 388 507 085 0.31 366 815 871 273 0.42 524  203 1 378 358 0.38
 Mean 174 380 525 146 0.33 344 835 840 827 0.41 519  214 1 365 972 0.38
2000         
 Erasmus MC 20 277 55 337 0.37 48 897 94 979 0.51 69  173 150 316 0.46
 FHCRC 22 271 63 373 0.35 39 076 92 434 0.42 61  347 155 807 0.39
 MGH-HMS 21 532 60 774 0.35 38 375 92 187 0.42 59  907 152 961 0.39
 PIRE 40 496 90 001 0.45 50 943 110 800 0.46 91  439 200 802 0.46
 Rice-MDA 28 365 55 988 0.51 42 351 86 863 0.49 70  716 142 851 0.50
 Yale 23 559 62 628 0.38 45 165 96 794 0.47 68  723 159 422 0.43
 Mean 26 083 64 684 0.40 44 135 95 676 0.46 70  218 160 360 0.44
* ATC = Actual Tobacco Control; CTC = Complete Tobacco Control; NTC = No Tobacco Control. The realized benefits of ATC are estimated by the difference 
(NTC–ATC); the potential total benefits are estimated by the difference (NTC–CTC); the proportion realized is given by the quotient of realized benefits and total 
potential benefits: (NTC–ATC)/(NTC–CTC). The six study groups that produced models are as follows: Erasmus MC = Erasmus Medical Center, Rotterdam, the 
Netherlands; FHCRC = Fred Hutchinson Cancer Research Center, Seattle, WA; MGH-HMS = Massachusetts General Hospital and Harvard Medical School, 
Cambridge, MA; PIRE = Pacific Institute for Research and Evaluation, Calverton, MD; Rice-MDA = Rice University and M.D. Anderson Cancer Center, Houston, 
TX; and Yale = Yale University, New Haven, CT.
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in these subgroups because of identifiability issues. The FHCRC 
group did fit period and cohort effects to never smokers alone and 
to current smokers and former smokers separately, but the original 
model in which these effects are applied equally to all groups 
described the data better as judged by the Akaike Information 
Criterion Statistics (28).
Overall, our study shows that changes in smoking behaviors led 
to a substantial reduction in the lung cancer mortality that would 
have been expected had the smoking trends in the 1950s continued 
into the future. Our analysis was conducted through to the year 2000, 
the latest year for which we were able to obtain sufficiently detailed 
data when this project was initiated. Consistent with trends for 
continued gains due to past tobacco control policies, smoking 
prevalence continued to fall from 23.2% in 2000 to 20.6% in 2008. 
Much of this decrease can be attributed to tobacco control policies, 
especially the cigarette price increases in 1998–1999 (29).
There are also other limitations to our study. We did not 
quantitatively assess the relative contributions made by changing 
patterns of smoking initiation and cessation to decreases in lung 
cancer mortality. It is clear, however, that most of the benefits 
of tobacco control policies during the period 1975–2000 have 
accrued from smoking cessation because changing patterns of 
smoking initiation would have impacted only individuals who 
were aged 55 or younger in 2000 and thus younger than the age 
at which lung cancer mortality begins to increase rapidly. Also, 
our numbers are likely to greatly underestimate the overall health 
impact of tobacco control efforts because they neither consider 
the substantial impact of non-cigarette forms of tobacco use (eg, 
cigars and pipes) nor the impact of tobacco smoking behaviors on 
diseases other than lung cancer. Smoking-associated diseases other 
than lung cancer, such as cardiovascular disease, were outside the 
scope of this work.
The results of this article show the dramatic impact of the 
reduction in smoking associated with tobacco control efforts in the 
second half of the 20th century on lung cancer mortality during the 
period 1975–2000. Even though other factors, including genetic 
polymorphisms (27), contribute to lung cancer risk, the vast majority 
of lung cancer cases could be eliminated by eliminating smoking. Our 
results indicate that only approximately 30% of the total lung 
cancer deaths that could have been averted had tobacco control been 
complete were actually averted. This is because smoking rates took 
time to decline after the first Surgeon General’s Report in 1965; 
smokers’ risk of lung cancer remains elevated for many years after 
smoking cessation and a sizable fraction of the population continued 
to smoke.
Clearly, further reductions in smoking rates will be required to 
reduce lung cancer incidence and mortality rates substantially. The 
recently reported 20% reduction in lung cancer mortality (30) 
as a result of early detection using low-dose spiral CT suggests that 
screening of high-risk individuals may play a role in reducing 
mortality from this disease. Because risk of lung cancer remains 
elevated for a long time among smokers who quit, effective screening 
techniques may have a role in reducing lung cancer mortality 
among ex-smokers. However, continued implementation of evidence-
based tobacco control policies, programs, and services remains 
the most promising approach to reducing the burden of lung 
cancer.
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